Save

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

PHASE3RECRUITING

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years.

The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.

Simpliy with AI

Study details:

This is a pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS. The duration of the double-blind period per patient is estimated to be maximum of 122 weeks, a Screening and Qualification period of between 6 and 14 weeks (including a 4 week period to complete the assessments required for Screening, Titration (if required, up to 4 weeks) and, 6-weeks of Stabilization, a 104-week Treatment period, and up to a 4-week off-treatment Follow-up period. The treatment duration of the OLE period per patient is estimated to be a minimum of 104 weeks (2 years) with a 4-week off-treatment Follow-up period.

The total study duration (double-blind period and OLE combined) is currently estimated to be a minimum of 230 weeks.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Patients must be 12 to 80 years old

A diagnosis of primary FSGS, genetic FSGS, or FSGS of undetermined cause. Confirmed by kidney biopsy or documentation of a genetic mutation in a podocyte protein associated with FSGS

Must be either receiving an ARB at the maximal tolerated dose or willing to transition

If taking corticosteroids, the dosage must be stable for ≥4 weeks prior to Screening and during Stablization

If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, or endothelin receptor antagonists (ERAs, including dual antagonists), the dose and regimen must be stable for ≥12 weeks prior to Screening and during Stablization

Urine PCR >1.5 g/g (>169.5 mg/mmol) or 24-hour total protein >1.5 g/day based on 24-hour urine collection during Screening.

Estimated GFR ≥25 mL/min/1.73 m2 at Screening

Seated blood pressure ≤160/100 mm Hg (mean of 3 values) (patients ≥18 years of age) or between the 5th and 95th percentile for age, sex, and height (patients <18 years of age) at Screening.

Body weight ≥35 kg (all patients) AND a BMI ≤40 kg/m2 (patients ≥18 years of age) or between the 5th and 98th percentile for age and sex (patients <18 years of age) at Screening.

A female patient is eligible to participate if she is not pregnant or planning to become pregnant during the study, not breastfeeding, and at least one of the following conditions applies: 1. Is not of childbearing potential 2. If of childbearing potential and beginning at menarche, agrees to use a highly effective method of contraception consistently during the treatment period.

A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception

A patient or parent/legal guardian (as appropriate) who is capable of giving signed informed consent, and where required, the patient is capable of providing assent.

Exclusion criteria

Has FSGS secondary to another condition.

History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as glycated hemoglobin [HbA1c] >8%)

History of lymphoma, leukemia, or any active malignancy within the past 2 years

Active clinically significant hepatobiliary disease.

Documented history of heart failure (New York Heart Association Class III/IV) or a major adverse cardiac event within 12 weeks prior to Screening.

Has a physical, medical, or psychological condition, that in the opinion of the Investigator, may interfere with the evaluation the study.

The patient has a history of alcohol or illicit drug use disorder within 1 year prior to Screening.

Had a prior organ transplant or stem cell transplant, with the exception of corneal transplant.

Positive screening assessment for viral hepatitis B surface antigen, or anti-hepatitis C virus antibody AND positive HCV RNA, or human immunodeficiency virus 1 and 2.

Serum potassium levels >5.5 mmol/L at Screening.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2 × upper limit of normal (ULN) at Screening

Treatment with immunosuppressant biological drugs, calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 12 weeks prior to Screening.

History of serious side effects or allergic response to an angiotensin II antagonist or has a known sensitivity to any components in the Investigational Product.

Unable to swallow oral medication.

Prior participation in any Dimerix-sponsored DMX-200 clinical study.

Participation in a clinical study with an Investigational Product within 28 days or 5 half-lives (whichever is longer) prior to Screening or plans to participate in another study during the course of this study.

Are study site personnel directly affiliated with this study and their immediate families.

Simplify with AI

Eligibility

Age eligible for study : 12 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2022-05-30

Primary completion: 2024-06-01

Study completion finish: 2026-06-01

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT05183646

Intervention or treatment

DRUG: DMX-200

DRUG: Placebo

Conditions

• FSGS

Condition: FSGS
DRUG: DMX-200 and other drugs
Brisbane, Not Specified, Australia and more
Sponsor: Dimerix Bioscience Pty Ltd

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

ACTION3 Investigational Site 1

Research sites nearby

Select from list below to view details:

ACTION3 Investigational Site 1
Brisbane, Not Specified, Australia
ACTION3 Investigational Site 2
Melbourne, Not Specified, Australia
Action3 Investigator Site 6
Melbourne, Not Specified, Australia
ACTION3 Investigational Site 4
Sydney, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: DMX-200 (repagermanium) Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks) OLE: Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the OLE period (108-212 weeks)	DRUG: DMX-200 DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
PLACEBO_COMPARATOR: Placebo Patients will receive 120 mg immediate release capsules of Placebo twice daily	DRUG: Placebo Patients will receive 120 mg capsules of Placebo twice daily

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Evaluate the efficacy of DMX-200 in terms of urine PCR in patients with FSGS who are receiving an ARB.	Percent change in urine PCR (based on 24-hour urine collection)	Baseline to Week 35
Evaluate the efficacy of DMX-200 in terms of eGFR slope in patients with FSGS who are receiving an ARB (Analysis at week 35 and Week 104).	Slope of eGFR	Baseline to Week 104
OLE - Assess the long-term safety and tolerability of open-label treatment with DMX-200 in patients with FSGS who are receiving an ARB.	Incidence and severity of treatment-related AEs and any AESIs and SAEs following long-term treatment with DMX-200.	Double-blind baseline to Week 216

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Evaluate the incidence and severity of AEs with treatment of DMX-200 in patients with FSGS who are receiving an ARB.	Incidence and severity of AEs and clinically significant changes following treatment with DMX-200 compared with placebo.	Baseline to Week 104
To evaluate the effect of DMX-200 on kidney function parameters including proteinuria in patients with FSGS who are receiving an ARB.	Proportion of responders and non-responders following treatment with DMX-200 compared with placebo. Proportion of patients on treatment with DMX-200 compared with placebo that meet a composite endpoint of worsening in kidney function.	Baseline to Week 104
OLE - Assess the long-term efficacy of open-label treatment with DMX-200 in patients with FSGS who are receiving an ARB.	Slope of eGFR and percent change in urine PCR	From Week 108 (Baseline) at each visit
OLE - Evaluate the long-term effect of open-label treatment with DMX-200 on kidney function parameters in patients with FSGS who are receiving an ARB.	Proportion of patients on treatment with DMX-200 that meet a composite endpoint of worsening in kidney function.	Double blind baseline to Week 216

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB